Hempsana: Cannabis-Infused Products for Wellbeing

Hempsana is a Canadian cannabis company incorporated under the Federal laws of Canada. It is a specialized manufacturer of cannabis derivatives, focus …

Hempsana cannabis products

Poised to become a global supplier as markets open

Hempsana is a Canadian cannabis company incorporated under the Federal laws of Canada. It is a specialized manufacturer of cannabis derivatives, focused on Extraction & Purification and End-Product Manufacturing. Further, the company’s EU-GMP compliant facility, in Goderich Ontario, is licensed under Health Canada’s Standard Processing and Industrial Hemp Licences.

Moreover, Hempsana is focusing on producing consistent high-quality cannabis extracts for use in finished product development, including vapeables, topical creams and infused consumables. Their vision is to offer carefully crafted cannabinoid extracts for modern consumers who want a safe natural alternative that fits seamlessly into today's healthy lifestyles.  With that in mind, they have built Hempsana as the go-to supplier of safe, high-quality cannabis concentrate raw materials, finished products, processing, packaging and labelling for ready-to-sell cannabis products, focussing on CBD, CBG as well as CBN as primary extracts.

Additionally, Hempsana uses safe innovative processing, strict quality controls and extensive in-process testing. This ensures products are formulated consistently and, most importantly, safe for consumers.

For more information on Hempsana Inc. (CSE: HMPS) please click the request investor info button.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info